| |
Download this report for insights on the current market, trends & strategic partnerships driving innovation in orphan drugs. View the report.
|
|
|
Tuesday, January 31, 2023 | 11:00am ET This Webinar will highlight the comprehensive set of tools that Aldevron developed to support advancing mRNA projects to clinic. In addition, an overview of the technology transfer program, analytical and process characterization, release, and stability will be discussed with an insight into Aldevron’s integrated CMC capabilities ranging from transcript design and product profile definition through encapsulation and fill/finish. Register now.
|
|
| By Nick Paul Taylor A consortium featuring AstraZeneca has secured funding to advance the delivery of nucleic acids, teeing the collaborators up to create new methods for getting oligonucleotide therapies to target tissues. |
|
|
|
By Nick Paul Taylor Midatech Pharma’s plans to pivot past its cash crunch have come unstuck. After securing financing and striking a deal to buy Bioasis Technologies, Midatech put its plans to a vote—only for investors to shoot down the proposals and leave the drug delivery specialist with weeks to find an alternative option. |
By Nick Paul Taylor Researchers have generated more preclinical evidence that intranasal delivery can get antibodies to the brain, presenting data that suggest the administration route can achieve concentrations close to those provided by invasive intrathecal infusions. |
By Nick Paul Taylor Piezo Therapeutics has emerged as the latest startup focused on the delivery of nucleic acids, launching with $2 million in seed funding and a platform that combines electric pulses and microneedles. |
|
Download this executive summary to learn more about safe and successful HPAPI product development and manufacturing using micronization. Download today!
|
|
By Kevin Dunleavy Since the start of the decade, big pharma companies from Europe and the United States have descended on China to get in on the country’s biotech boom. The latest big pharma player to get a piece of the action however is closer to home. Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. |
By Eric Sagonowsky As the biopharma industry moves beyond its groundbreaking pandemic response, we're looking for leaders with ideas that'll shape the future of the industry. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we take you inside Fierce's JPM Week event. Listen in on snippets from a lively panel discussion on how companies will navigate the drug pricing policies the Biden administration rolled out just last year. And hear from Christine Roth, head of Bayer's oncology strategic business unit, about the company's plans to become a strong competitor in cancer. |
|
|---|
|
|
|
Thursday, February 2, 2023 | 11am ET / 8am PT Regulators have made it abundantly clear - through recent guidance and inspection findings - that demonstrating sponsor oversight of an outsourced study is a critical requirement for TMF health and inspection-readiness. Join this webinar to discover how global biopharmaceutical company Chiesi and its CRO partners collaborate to ensure ongoing oversight compliance, in the face of increasing documentation requirements and trial complexity. Register now.
|
|
| eBook Catalent’s Carla Vozone discusses the significant trends in the Orally Inhaled & Nasal Drug Delivery (OINDP) segment including large molecules and novel indications. Sponsored By: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
| |
|
